-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On December 22, Vivoryon announced that the FDA has granted its oral small molecule drug varoglutamstat (PQ912, SIM0408) fast track qualification for the treatment of early Alzheimer’s disease (AD)
Simcere Pharmaceuticals reached a $500 million cooperation with Vivoryon in June this year, and obtained the development and commercialization of two types of neurotoxic amyloid N3pE (pGlu-Abeta) in Greater China, including Varoglutamstat.
Alzheimer's disease (AD) is the most common type of senile dementia.
Varoglutamstat is an oral small-molecule inhibitor targeting glutaminyl peptide cyclotransferase (QPCT).
Varoglutamstat can prevent the production of N3pE amyloid by inhibiting QPCT and its isoenzymes
Neurotoxic amyloid N3pE can trigger AD-related pathological pathways
Varoglutamstat's pharmacy, toxicology, main pharmacodynamics and other properties have been verified by preclinical studies
Currently, there is no drug with the same target on the market globally